Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 + Ipilimumab in Advanced Melanoma
NCT02452281Phase 2Withdrawn
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vitespen in melanoma. Primary endpoints: Safety (Adverse Events) at 2 years and Immunological Response at 2 years. Planned start Dec 2015; status: withdrawn.
02
Drugs
vitespen
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02452281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452281.